Translational research in neuroendocrine tumors: pitfalls and opportunities

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncogene

• Publication date

  2017-04-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2016.316PMID 27641330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

  2016cited by this paper
• Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).

  2015cited by this paper
• Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas

  2015cited by this paper
• SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).

  2015cited by this paper
• Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors

  2015cited by this paper
• A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial

  2015cited by this paper
• Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.

  2015cited by this paper
• Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.

  2015cited by this paper
• Mechanisms of local invasion in enteroendocrine tumors: identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors.

  2015cited by this paper
• Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

  2015cited by this paper
• Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

  2015cited by this paper
• A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

  2015cited by this paper
• Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.

  2015cited by this paper
• Hallmarks of alternative splicing in cancer

  2014cited by this paper
• 1132OEVEROLIMUS (EVE) FOR THE TREATMENT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET): FINAL OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, MULTICENTER PHASE III TRIAL (RADIANT-3).

  2014cited by this paper
• Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges

  2014cited by this paper
• Gastroenteropancreatic endocrine tumors.

  2014cited by this paper
• Translational research in oncology—10 years of progress and future prospects

  2014cited by this paper
• Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors

  2014cited by this paper
• Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors

  2014cited by this paper
• The genomic landscape of small intestine neuroendocrine tumors.

  2013cited by this paper
• Neuroendocrine tumours: cracking the epigenetic code.

  2013cited by this paper
• Somatic mutation of CDKN1B in small intestine neuroendocrine tumors

  2013cited by this paper
• The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

  2013cited by this paper
• Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).

  2013cited by this paper
• Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches

  2013cited by this paper
• Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.

  2013cited by this paper
• sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.

  2013cited by this paper
• PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

  2012cited by this paper
• RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe.

  2012cited by this paper
• The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells

  2012cited by this paper
• Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy

  2012cited by this paper
• A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors

  2012cited by this paper
• Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

  2012cited by this paper
• Molecular pathology and genetics of pancreatic endocrine tumours.

  2012cited by this paper
• Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

  2011cited by this paper
• Altered Telomeres in Tumors with ATRX and DAXX Mutations

  2011cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

  2011cited by this paper
• Epigenetics in alternative pre-mRNA splicing.

  2011cited by this paper
• A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• A refined molecular taxonomy of breast cancer

  2011cited by this paper
• Pancreatic endocrine tumors

  2011cited by this paper
• First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• New Epigenetic Drivers of Cancers

  2011cited by this paper
• Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

  2010cited by this paper
• Relationship Between Quality of Life and Health-Related Measures Including Symptoms, Biochemical Markers And Tumor Burden

  2010cited by this paper
• Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

  2010cited by this paper
• O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

  2009cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Activity of sunitinib in patients with advanced neuroendocrine tumors.

  2008cited by this paper
• Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

  2008cited by this paper
• O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors

  2008cited by this paper
• Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

  2008cited by this paper
• The functional characterization of normal and neoplastic human enterochromaffin cells.

  2006cited by this paper
• Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.

  2006cited by this paper
• Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour

  2005cited by this paper
• The molecular genetics of gastroenteropancreatic neuroendocrine tumors

  2005cited by this paper
• A mouse model of carcinoid syndrome and heart disease.

  2004cited by this paper
• Conditional Inactivation of the Men1 Gene Leads to Pancreatic and Pituitary Tumorigenesis but Does Not Affect Normal Development of These Tissues

  2004cited by this paper
• Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.

  2003cited by this paper
• Of Mice and MEN1: Insulinomas in a Conditional Mouse Knockout

  2003cited by this paper
• Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Endocrine Neoplasms

  2003cited by this paper
• A 5‐decade analysis of 13,715 carcinoid tumors

  2003cited by this paper
• Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice.

  2003cited by this paper
• VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.

  2002cited by this paper
• Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors

  2001cited by this paper
• Animal Model A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake

  2001cited by this paper
• A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.

  2001cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity

  2000cited by this paper
• Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia

  1999cited by this paper
• A causal role for E-cadherin in the transition from adenoma to carcinoma

  1998cited by this paper
• Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis

  1996cited by this paper
• The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors.

  1996cited by this paper
• Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma.

  1995cited by this paper
• Characterization of a Human Pancreatic Carcinoid in Vitro: Morphology, Amine and Peptide Storage, and Secretion

  1994cited by this paper
• A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis

  1994cited by this paper
• Praomys (Mastomys) natalensis: a model for gastric carcinoid formation.

  1992cited by this paper
• Induction of angiogenesis during the transition from hyperplasia to neoplasia

  1989cited by this paper
• Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

  1985cited by this paper
• Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

  1984cited by this paper
• The use of drugs in combination for the treatment of cancer: rationale and results.

  1973cited by this paper

• Germline Mutations in DNA Repair Genes in Patients with Pancreatic Neuroendocrine Neoplasms: Diagnostic and Therapeutic Implications

  2025cites this paper
• Overlapping Presentations and Diverse Genetic Defects Characterize Neuroendocrine Neoplasms in a Mexican Cohort

  2025cites this paper
• Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin

  2022cites this paper
• The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities

  2022cites this paper
• Preclinical Models of Neuroendocrine Neoplasia

  2022cites this paper
• PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors

  2021cites this paper
• Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias

  2021cites this paper
• A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease outperforms CgA and has Surgical and Clinical Utility.

  2021cites this paper
• Title : Cdk 5 drives formation of heterogeneous pancreatic neuroendocrine tumors

  2021cites this paper
• Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors

  2021cites this paper
• Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors

  2020cites this paper
• A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.

  2020cites this paper
• Local Coverage Determination (LCD): Biomarker Testing for Neuroendocrine Tumors/Neoplasms (L37851)

  2020cites this paper
• Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection

  2020cites this paper
• Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review

  2020cites this paper
• An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts.

  2020cites this paper
• Time for a change and to adopt a novel molecular genomic approach in NETs

  2019cites this paper
• Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms

  2019cites this paper
• EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors

  2019cites this paper
• Mouse models in endocrine tumors.

  2019cites this paper
• The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.

  2019cites this paper
• Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms

  2019cites this paper
• Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium

  2018cites this paper
• Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.

  2018cites this paper
• Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors

  2018cites this paper
• Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms

  2018cites this paper
• Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors

  2018cites this paper
• Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors

  2018cites this paper
• PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors Tumors

  year unknowncites this paper
• Evaluation of DNA Damage in Patients with a Neuroendocrine Tumor Nöroendokrin Tümörlü Hastalarda DNA

  year unknowncites this paper
• Evaluation of DNA Damage in Patients with a Neuroendocrine Tumor

  year unknowncites this paper